Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Neoplasms × belzutifan × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 13 Kidney Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Glioblastoma 1

Interventions

pembrolizumab 27 Cyclophosphamide 17 Nivolumab 16 fludarabine 8 Surveys and Questionnaires 8 Paclitaxel 8 Exercise 8 Doxorubicin 8 Carboplatin 8 Bevacizumab 8 budigalimab 7 atezolizumab 7 Radiotherapy 7 Fluorouracil 7 Docetaxel 7 Dexamethasone 7 Blood Specimen Collection 7 venetoclax 6 lenvatinib 6 cabozantinib 6 Rituximab 6 Prednisone 6 Pemetrexed 6 Oxaliplatin 6 Gemcitabine 6 fludarabine phosphate 5 durvalumab 5 avelumab 5 Vincristine 5 Leucovorin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡